Prof Research published a new market report on the atrophic gastritis treatment market. It presents the largest 14 vendors in the atrophic gastritis treatment market. The report is a professional and in-depth study on the current state of the global atrophic gastritis treatment market. The report provides key statistics on the market of atrophic gastritis treatment.  It is a valuable source of guidance and direction for companies and individuals interested in the atrophic gastritis treatment industry.

The global atrophic gastritis treatment market was valued to be 4,835.67 million USD in 2020. The atrophic gastritis treatment production value is anticipated to have grown with a CAGR of 3.35% in the coming years to reach 5,788.06 million USD in 2026.

Takeda Pharmaceutical is the largest vendor of atrophic gastritis treatment in the world, it has a market share of 8.1% in value. Takeda comprises a single operating segment and is engaged in the research, development, manufacturing, marketing and out-licensing of pharmaceutical products. Its therapeutic area includes Gastroenterology, Rare Diseases, Rare Hematology and Hereditary Angioedema.

AstraZeneca is the second-largest vendor of atrophic gastritis treatment in the world, it has a market share of 5.1% in value. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Teva Pharmaceutical is the third-largest vendor of atrophic gastritis treatment in the world, it has a market share of 3.9% in value. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Abbott is the fourth-largest vendor of atrophic gastritis treatment in the world, it has a market share of 3.7% in value. it sells medical devices, diagnostics, branded generic medicines and nutritional products.